Merck Signs $2B Deal with Hengrui Pharma for Cardi...
Category : Licensing/Collaboration Deal 28 March 2025For an investigational oral ipoprotein(a) inhibitor for cardiovascular disease Merck, known as MSD o...
For an investigational oral ipoprotein(a) inhibitor for cardiovascular disease Merck, known as MSD o...
AdjuTec Pharma AS, a privately held company developing antibiotic resistance breakers, announces tha...
Bio-Thera Solutions, a China-based biopharmaceutical company developing a pipeline of innovative the...
Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, announced i...
The United Laboratories International Holdings Limited (TUL), a firm mainly engaged in the R&D,...